Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 2: Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Deborah Stephens CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 1: Optimizing the First-Line Management of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Dr Jennifer Brown CME information and select publications

Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, including the following topics: Introduction: First-Line Treatment of Chronic Lymphocytic Leukemia (0:00) Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax; Venetoclax Consolidation (36:57) Noncovalent BTK Inhibitors; Pirtobrutinib (42:59) CAR T-Cell Therapy; Lisocabtagene Maraleucel (51:26) Richter's Transformation (56:31) CME information and select publications

Featuring perspectives from Dr Shaji Kumar, including the following topics: Introduction (0:00) Case: A woman in her early 70s with standard-risk newly diagnosed multiple myeloma (NDMM), "borderline transplant-eligible," receiving daratumumab-RVd, with transportation limitations and missed treatments — Neil Morganstein, MD (11:50) Case: A woman in her early 50s with Stage III, high-risk NDMM (1q21+), multiple bone lesions and acute renal impairment after RVd and transplant, now on the DRAMMATIC trial — Vignesh Narayanan, MD (24:43) Cases: A man in his early 60s with relapsed t(11;14) multiple myeloma (MM) and renal failure after RVd and ASCT, now on venetoclax/bortezomib/dexamethasone and a woman in her mid 50s with high-risk t(11;14) smoldering MM — Amany R Keruakous, MD, MS and Hans Lee, MD (32:59) Case: A man in his late 70s with transplant-ineligible NDMM who received daratumumab with lenalidomide/dexamethasone but discontinued daratumumab because of a severe rash — Yanjun Ma, MD (41:32) Case: A man in his mid 80s with a history of non-muscle-invasive bladder cancer, now with multiregimen-refractory MM and biochemical disease progression — Spencer Henick Bachow, MD (45:49) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 2: Metastatic Breast Cancer — Dr Joyce O'Shaughnessy CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 1: Localized Breast Cancer — Professor Peter Schmid CME information and select publications

Featuring perspectives from Dr Joyce O'Shaughnessy and Prof Peter Schmid, including the following topics: Introduction: POSITIVE Trial — Temporary Interruption of Endocrine Therapy for Pregnancy (0:00) Metastatic Breast Cancer — Dr O'Shaughnessy (7:44) Localized Breast Cancer — Prof Schmid (41:25) CME information and select publications

Featuring perspectives from Drs Courtney DiNardo and Mark Levis, including the following topics: Introduction (0:00) Case: A man in his early 80s with newly diagnosed acute myeloid leukemia (AML) with significant comorbidities receives decitabine/venetoclax — Rebecca L Olin, MD, MSCE (7:36) Cases: A man in his mid 50s after 7 + 3 and allogeneic stem cell transplantation (SCT) presents with myeloid sarcoma; a man in his late 70s after 7 + 3 and allogeneic SCT presents with myeloid sarcoma — Spencer H Bachow, MD and Ranju Gupta, MD (12:16) Case: A man in his late 30s with core binding factor AML after induction CLAG-M with gemtuzumab ozogamicin followed by high-dose cytarabine x 4 — Anna Halpern, MD (18:10) Case: A woman in her mid 60s with newly diagnosed del(5q) AML with monocytic differentiation and multiple mutations (GATA2, BCOR, NF1 and RUNX1) receives azacitidine and venetoclax — Bhavana (Tina) Bhatnagar, DO (31:05) Selection of Therapy for Patients with AML (35:20) Cases: A man in his early 50s with therapy-related AML with an MLL mutation who receives CPX-351; a man in his early 70s with secondary AML with an IDH mutation — Amany R Keruakous, MD, MS and Priya Rudolph, MD, PhD (41:42) Case: A man in his early 70s with recurrent AML with an IDH2 mutation receives enasidenib and develops differentiation syndrome/disease progression — Dr Halpern (50:00) CME information and select publications

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 1: Selection of Therapy for Older and Younger Patients with Acute Myeloid Leukemia (AML) — Dr Courtney DiNardo CME information and select publications

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment of AML with Targetable Mutations — Dr Andrew Wei CME information and select publications

Featuring an interview with Dr Manish Shah, including the following topics: Biologic rationale for targeting PD-1/PD-L1 in upper GI cancers (0:00) Management of HER2-positive gastric cancers (6:38) Activity and tolerability of therapies targeting claudin 18.2 for patients with GI malignancies (15:48) CME information and select publications

Featuring an interview with Dr Manish Shah, including the following topics: Role of targeted and immunotherapy regimens for upper GI cancers (0:00) Future of CAR T-cell therapy for patients with gastric cancer (11:26) Case: A man in his mid 60s with HER2-positive gastroesophageal adenocarcinoma (15:59) Case: A woman in her mid 70s with newly diagnosed HER2-negative, pMMR gastric cancer (29:57) Case: A man in his mid 50s with dMMR, HER2-negative gastric cancer (37:32) CME information and select publications

Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics: Front-Line Treatment of Multiple Myeloma (MM) Introduction (0:00) Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49) Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05) Dr Orlowski presentation (15:45) Integration of Novel Therapies into the Management of Relapsed/Refractory MM Cases: A transplant-eligible man in his late 60s with well-controlled HIV-1 and standard-risk NDMM and a man in his late 60s with high-risk, t(4;14) multiregimen-refractory MM with travel limitations who receives belantamab mafodotin — Neil Morganstein, MD and Syed Farhan Zafar, MD (29:19) Cases: A woman in her early 70s who receives daratumumab, bortezomib and dexamethasone for relapsed MM 6 years after RVd followed by autologous stem cell transplant and maintenance bortezomib, and a man in his mid 50s with NDMM who received RVd followed by maintenance lenalidomide, which was discontinued by the patient after 1 year — Henna Malik, MD and Dr Rupard (35:50) Dr Fonseca presentation (41:57) Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM Case: A man in his early 70s with NDMM who receives induction daratumumab/RVd — Spencer H Bachow, MD (52:27) Cases: A woman in her early 60s with relapsed MM and pathologic fractures who received induction daratumumab/Rd and palliative radiation therapy for bone disease, and a woman in her mid 70s with refractory MM 6 months after induction daratumumab/RVd lite — Dr Bhatnagar and Kimberly Ku, MD (57:00) Dr Raje presentation (1:01:12) Bispecific Antibodies in the Treatment of MM Case: A man in his early 70s with t(4;14) NDMM who initiates RVd, which is put on hold to treat severe depression — Warren S Brenner, MD (1:14:38) Case: A woman in her mid 70s with multiregimen-refractory del(17p) MM who is considered for BCMA-directed therapy — Dr Bachow (1:16:28) Dr Berdeja presentation (1:22:18) Other Investigational Novel Agents for MM Case: A woman in her mid 80s with congestive heart failure and t(4;14), t(11;14) and t(14;16) MM who receives dose-reduced RVd and develops chalazion eye toxicity — Jennifer L Dallas, MD (1:36:23) Dr Lonial presentation (1:39:34) CME information and select publications

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics: Diffuse Large B-Cell Lymphoma (DLBCL) Introduction (0:00) Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36) Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Stage IE DLBCL and a man in his early 80s with Stage IIIB DLBCL, GCB type and LVEF 35% to 40% due to prior myocardial infarction and coronary artery disease — Bhavana (Tina) Bhatnagar, DO and Yanjun Ma, MD (7:10) Dr Friedberg presentation (11:54) Follicular Lymphoma Case: A man in his late 60s with progressive Grade I/II follicular lymphoma after observation for many years — Neil Morganstein, MD (29:07) Case: A woman in her early 60s with Grade II follicular lymphoma who received bendamustine/rituximab and maintenance rituximab — Jennifer L Dallas, MD (33:11) Dr Nastoupil presentation (38:36) Hodgkin Lymphoma Case: A woman in her early 80s with newly diagnosed classical Hodgkin lymphoma — Kapisthalam (KS) Kumar, MD(51:21) Cases: A woman in her late 30s with newly diagnosed classical Hodgkin lymphoma and a man in his early 60s with newly diagnosed Stage IV classical Hodgkin lymphoma who receives brentuximab/vedotin with AVD (doxorubicin/vinblastine/dacarbazine) — Susmitha Apuri, MD and Amany R Keruakous, MD, MS (55:21) Dr Smith presentation (1:10:17) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma Cases: A man in his late 50s who presents with a large cecal mass and mesenteric adenopathy and is diagnosed with "double hit" DLBCL and a woman in her early 70s with DLBCL treated with R-CHOP, now with progressive disease 6 months later — Vignesh Narayanan, MD and Rahul Gosain, MD (1:14:56) Case: A woman in her early 70s with rapid relapse after R-CHOP then R-ICE (rituximab/ifosfamide/carboplatin/etoposide) and ASCT who achieves a complete response with CAR T-cell therapy but experiences significant pancytopenias — John Yang, MD (1:22:10) Dr Maloney presentation (1:25:24) Mantle Cell Lymphoma (MCL) Case: A man in his late 70s with high-risk relapsed MCL after BR and maintenance rituximab x 3 years — Raman Sood, MD (1:39:10) Case: A man in his mid 80s who received prior treatment for prostate cancer and presents with low-volume indolent MCL with a TP53 mutation — Spencer H Bachow, MD (1:42:47) Dr Kahl presentation (1:45:29) CME information and select publications

Featuring an interview with Dr Scott Tagawa, including the following topics: Sequencing therapies for patients with metastatic urothelial bladder cancer (UBC) (0:00) Case: A man in his mid 80s with UBC with multiple lung and lymph node metastases (4:55) Case: A woman in her mid 80s with metastatic UBC who is undergoing treatment with erdafitinib (46:21) Case: A man in his mid 60s with FGFR-altered metastatic UBC (49:45) CME information and select publications

Featuring a slide presentation and related discussion from Dr Scott Tagawa, including the following topics: Managing patients with FGFR-altered urothelial bladder cancer (UBC) (0:00) Antibody-drug conjugates as treatment for metastatic UBC (10:22) Strategies for using systemic therapies to treat metastatic UBC (27:31) CME information and select publications

Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer Introduction (0:00) Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) – 21-gene Recurrence Score® 22 — Alan B Astrow, MD (3:39) Case: A premenopausal woman in her mid 30s with 3.6-cm, ER/PR-positive, HER2-low (IHC 1+), sentinel node-positive (4/4) multifocal IDC after bilateral mastectomies, adjuvant AC-T and ovarian function suppression (OFS)/aromatase inhibitor, Ki67 50% — Laila Agrawal, MD (9:40) Dr Goetz presentation (19:43) Optimizing the Management of Localized ER-Positive Breast Cancer Case: A woman in her early 40s with 5.5-cm, ER/PR-positive, HER2-negative, node-positive (20/21) IDC after bilateral mastectomies, bilateral salpingo-oophorectomy, adjuvant AC-T and initiation of letrozole/abemaciclib, Ki-67 3% — Susmitha Apuri, MD (32:22) Case: A woman in her mid 50s with de novo ER-positive, PR-negative, HER2-negative ulcerated breast cancer with pulmonary and extensive spinal metastases — Jennifer L Dallas, MD (40:45) Dr Kaklamani presentation (45:32) Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 50s with ER/PR-positive, HER2-low mBC with a PI3KCA mutation who experiences a dramatic response to rechallenge with fulvestrant and a CDK4/6i (abemaciclib); now with progression and cytopenias — Kapisthalam (KS) Kumar, MD (59:07) Dr Kalinsky presentation (1:09:53) Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer Case: A premenopausal woman in her late 30s with ER/PR-positive, HER2-low (IHC 1+) IDC after adjuvant tamoxifen and OFS x 5 years, now with bone and liver metastases — Dr Agrawal (1:19:45) Dr Bardia presentation (1:24:29) Novel Strategies Under Investigation for Patients with HR-Positive mBC Case: A woman in her early 90s with ER/PR-positive, HER2-low (IHC 1+) mBC and progressive disease on multiple lines of endocrine and chemotherapy receives T-DXd — Dr Astrow (1:38:44) Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 2+) mBC who has received fulvestrant/abemaciclib, now receiving exemestane/everolimus – ESR1 and PIK3CA mutations — Dr Dallas (1:44:15) Dr Rugo presentation (1:49:58) CME information and select publications

Featuring perspectives from Drs Alexey Danilov, Matthew Davids, Lindsey Roeker, Philip Thompson and Prof Dr Arnon Kater, including the following topics: Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Introduction (0:00) Cases: A man in his early 90s with Rai Stage 0 CLL who underwent surveillance x 5 years and now develops cytopenias and transfusion-dependent anemia, and a woman in her late 60s with IGHV-unmutated CLL who develops night sweats, rapid doubling time of ALC — Bhavana (Tina) Bhatnagar, DO and Jennifer L Dallas, MD (3:18) Case: A man in his mid 50s with relapsed CLL after ibrutinib x 5 years now with disease progression — Amany R Keruakous, MD, MS (9:11) Dr Danilov presentation (16:47) Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL Case: A man in his late 70s with IGHV-unmutated CLL under observation for many years who develops B symptoms, cytopenias and lymphadenopathy — Henna Malik, MD (32:15) Prof Kater presentation (37:18) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations Case: A man in his early 70s with multiple musculoskeletal comorbidities and transportation limitations develops symptomatic IGHV-mutated CLL with cytopenias — Syed F Zafar, MD (51:08) Cases: A man in his mid 50s with del(17p) CLL and significant lymphadenopathy and B symptoms who receives acalabrutinib and a woman in her early 70s with IGHV-mutated CLL and a complex karyotype — Dr Keruakous and Spencer H Bachow, MD (55:10) Dr Davids presentation (1:03:01) Selection and Sequencing of Available Therapies for Relapsed/Refractory Disease Case: A man in his mid 70s with relapsed del(17p) CLL after ibrutinib with multiple chronic low-grade toxicities — Dr Bhatnagar (1:16:23) Dr Thompson presentation (1:20:56) Promising Investigational Agents and Strategies Case: A woman in her late 70s with CLL (p53, 11q, 13q mutations), disease progression on ibrutinib and a BTK C481S mutation detected on repeat testing — Dr Bachow (1:39:09) Case: A man in his late 70s who develops Richter's transformation while receiving obinutuzumab/venetoclax for CLL — Justin Peter Favaro, MD, PhD (1:43:12) Dr Roeker presentation (1:48:29) CME information and select publications

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31) Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05) Dr Tolaney presentation (18:44) Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 60s with an 8-cm, ER-negative, PR-positive, HER2-positive IDC and positive nodes bilaterally after neoadjuvant TCHP and bilateral mastectomies with no residual disease — Henna Malik, MD (31:12) Case: A woman in her late 50s with Stage IIIA, ER/PR-negative, HER2-positive, node-positive IDC with residual disease after neoadjuvant TCHP and mastectomy — Laila Agrawal, MD ()35:29 Dr Krop presentation (42:56) Management of HER2-Positive Breast Cancer with CNS Metastases Case: A woman in her early 90s with "mild" dementia and ER/PR-negative, HER2 IHC 1+ IDC with symptomatic chest wall recurrence after neoadjuvant paclitaxel/trastuzumab and lumpectomy — Alan B Astrow, MD (54:54) Case: A woman in her late 40s with a triple-positive multifocal IDC with a gBRCA2 mutation and HER2-negative axillary nodes after neoadjuvant TCHP and bilateral mastectomies with significant response in the breast but 49 positive nodes — Zanetta S Lamar, MD (1:00:01) Dr Hamilton presentation (1:06:51) Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer Cases: A premenopausal woman in her late 30s with a triple-positive IDC who develops brain metastases while receiving THP; A woman in her late 60s with an ER/PR-negative, HER2-positive IDC who develops brain metastases after first-line THP and second-line T-DM1 — Kelly Yap, MD & Rohit Gosain, MD (1:20:46) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive mBC treated with paclitaxel/trastuzumab, then T-DXd on progression — Joanna Metzner-Sadurski, MD (1:29:40) Dr Modi presentation (1:40:51) Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy Case: A woman in her early 60s with recurrent triple-positive mBC whose disease converts to HER2-negative, PIK3CA-positive at the time of progression — Dhatri Kodali, MD (2:01:10) Dr Hurvitz presentation (2:05:08) CME information and select publications

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics: Keys to evaluating genetics in patients with ovarian cancer (0:00) Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35) Current status of PARP inhibitor use in the care of patients with ovarian cancer (18:45) Ongoing studies evaluating the combination of PARP and immune checkpoint inhibitors (24:37) CME information and select publications

Featuring perspectives from Dr Thomas Herzog, including the following topics: Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00) Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13) Sequential use of PARPi for patients with advanced ovarian cancer (16:56) Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06) Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22) Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02) CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 2: TROP2 and Other Investigational Targets for ADCs in Advanced NSCLC — Dr Alexander Spira CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 1: Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC) — Dr Helena Yu CME information and select publications

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics: Introduction What is an antibody-drug conjugate? (0:00) "HER2-Positive" Non-Small Cell Lung Cancer (NSCLC) Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42) Targeting HER3 in NSCLC Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23) TROP2-Directed Treatment Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57) Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32) Novel Agents Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15) CME information and select publications

Featuring perspectives from Dr S Vincent Rajkumar, including the following topics: Introduction: Requiem for Belantamab Mafodotin? Dawn of a New Era (0:00) Case: A man in his early 70s with multiregimen-refractory multiple myeloma (MM) receives idecabtagene vicleucel with Grade 1 cytokine release syndrome and persistent cytopenias — Jesús G Berdeja, MD (16:12) Case: A man in his mid 60s with multiregimen-refractory MM receives idecabtagene vicleucel with a 20-month response — Dr Berdeja (25:19) Case: A man in his late 50s with multiregimen-refractory MM received idecabtagene vicleucel in 2020 and is currently in complete remission — Natalie S Callander, MD (31:11) Case: A man in his early 60s with multiregimen-refractory MM receives the novel bispecific antibody WVT078 on a clinical trial — Dr Callander (41:02) Case: A man in his mid 70s with multiregimen-refractory MM receives teclistamab on a clinical trial — Dr Berdeja (51:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Omid Hamid, including the following topics: Current evolution in the care of patients with metastatic melanoma (0:00) Novel immunotherapeutic strategies for patients with untreated metastatic melanoma (1:47) Efficacy and safety of novel agents and combination treatments for patients with previously treated metastatic melanoma (16:28) Future directions in the care of patients with metastatic melanoma (25:13) CME information and select publications

Featuring an interview with Dr Omid Hamid, including the following topics: First-line treatment of metastatic melanoma (0:00) Triplet therapy for patients with BRAF-mutated metastatic melanoma (7:27) Case: A man in his mid 60s with previously untreated BRAF wild-type metastatic melanoma (15:44) Novel therapeutic strategies for patients with newly diagnosed melanoma (21:02) Immunotherapy strategies for second-line treatment of metastatic melanoma (29:25) Case: A man in his mid 40s with BRAF-mutated melanoma who experiences disease progression after treatment with ipilimumab and nivolumab (37:16) CME information and select publications

Featuring a slide presentation and related discussion from Dr Eric Sherman, including the following topics: Incidence and mortality of thyroid cancer and the thyroid cancer treatment pyramid (0:00) Available and emerging data with targeted therapies for thyroid cancer (9:01) Optimal genomic screening and selection of treatment for medullary thyroid cancer (26:58) CME information and select publications

Featuring an interview with Dr Eric Sherman, including the following topics: Changes in the incidence, mortality, and management of thyroid cancer in the past 20 years (0:00) Clinical presentation and histologic characteristics of thyroid cancer; genomic alterations associated with each histology (5:55) Initial management of thyroid cancer; current role of surgery and radioactive iodine in treatment algorithms (14:56) Current and future role of tumor biomarkers in treatment selection; emerging role of liquid biopsies in anaplastic thyroid cancer (20:23) Incidence and optimal treatment of brain metastases in patients with thyroid cancer; biologic rationale for tyrosine kinase inhibitors (TKIs) targeting VEGF and BRAF in thyroid cancer (24:20) Safety and tolerability of sorafenib and lenvatinib; management of BRAF-mutated disease (34:49) Management of tumors in patients with RET alterations or NTRK fusions; therapies for medullary tumors (39:28) Case: A woman in her early 60s with metastatic papillary thyroid cancer; ongoing research combining TKIs and immunotherapy for anaplastic thyroid cancer (50:35) Case: A man in his early 40s presenting with severe diarrhea and metastatic medullary thyroid cancer (1:00:54) CME information and select publications

Featuring perspectives from Prof Karim Fizazi and Prof Stéphane Oudard, including the following topics: Introduction: Journal Club — Karim Fizazi, MD, PhD and Stéphane Oudard, MD, PhD (0:00) Case: A man in his late 50s with Gleason 7 prostate cancer after prostatectomy/radiation therapy/androgen deprivation therapy (ADT) experiences biochemical recurrence 2 years later (PSA 0.5; doubling time 9 months) — Philip L Brooks, MD (10:58) Case: A man in his early 70s with a pacemaker presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC) after cerebrovascular accident — Nasfat Shehadeh, MD (28:50) Case: A man in his late 40s with multiple medical comorbidities presents with de novo mHSPC (PSA 19.4) and responds to ADT/docetaxel — Gurveen Kaur, MD (47:00) Case: A man in his mid 60s with de novo mHSPC receives leuprolide, and PSA levels decrease from 865 ng/mL to 1.34 ng/mL — Joanna Metzner-Sadurski, MD (50:38) Case: A man in his late 50s with mHSPC receives leuprolide, experiences disease progression 1.5 years later and responds to abiraterone/prednisone but on liquid biopsy is found to have an AR T878 mutation — Niyati A Nathwani, MD (54:30) Case: A man in his mid 60s presents with de novo metastatic prostate cancer and experiences disease progression on ADT + docetaxel, now with progressive disease on abiraterone/prednisone; germline CHEK2 mutation — Syed F Zafar, MD (56:51) CME information and select publications

Featuring a slide presentation and related discussion from Dr Jeffrey Zonder, including the following topics: Overview of amyloid light chain (AL) amyloidosis (0:00) Case: An African American man in his late 70s with transthyretin amyloidosis (8:39) Staging and prognosis of AL amyloidosis (14:11) Evolution of the amyloidosis treatment paradigm (26:39) Case: A woman in her late 70s with relapsed lambda light chain amyloidosis (44:33) Emerging data with novel therapies for AL amyloidosis (47:38) Case: A man in his early 60s with relapsed lambda light chain amyloidosis (52:18) CME information and select publications

Featuring an interview with Dr Jeffrey Zonder, including the following topics: Biology and symptomology of primary amyloidosis (0:00) Staging and prognosis for patients with amyloid light chain (AL) amyloidosis (10:21) Supportive care for patients with advanced disease (16:25) Current amyloidosis treatment paradigm (21:49) Monoclonal antibody therapy for patients with AL amyloidosis (31:38) CME information and select publications

Featuring perspectives from Dr Daniel Pollyea, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35) Defining AML versus Myelodysplastic Syndromes (6:06) Case: A man in his early 80s presenting with cytopenias and AML (8:56) Oral Decitabine/Cedazuridine (18:15) Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43) HMA/Venetoclax for Younger Patients (39:56) Translational Biology of AML: New Agents and Treatment Strategies (44:08) Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48) Anti-CD47 Antibody Magrolimab (51:08) Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22) CME information and select publications

Featuring perspectives from Dr Paul Richardson, including the following topics: Introduction (0:00) Case: A man in his early 60s with newly diagnosed Stage II standard-risk multiple myeloma — Ranju Gupta, MD (29:31) Case: A woman in her early 70s with Stage IIIA multiple myeloma who receives lenalidomide/bortezomib/dexamethasone → autologous stem cell transplant (ASCT) and discontinues maintenance lenalidomide after 3 years — Erik Rupard, MD (34:16) Case: A woman in her early 70s with relapsed myeloma after tandem ASCT who receives cyclophosphamide/bortezomib/dexamethasone, achieves minimum residual disease negativity and is now on maintenance ixazomib — Zanetta S Lamar, MD (39:01) Case: A woman in her early 70s with triple-class refractory t(11;14) multiple myeloma — Hans Lee, MD (43:47) Case: A man in his mid 60s with high-risk relapsed multiple myeloma after carfilzomib/lenalidomide/dexamethasone (KRd) induction, ASCT, maintenance KRd and 2 additional lines of therapy — Muzaffar H Qazilbash, MD (46:05) Faculty Survey (52:29) Journal Club with Dr Richardson (60:57) CME information and select publications

Featuring a slide presentation and related discussion from Dr Ruben Mesa, including the following topics: Efficacy and safety of FDA-approved JAK inhibitors for the management of myelofibrosis (MF) (0:00) Emerging JAK inhibitors under Phase III evaluation for MF (6:59) Current guidelines and strategies for managing MF (13:53) Emerging data with novel agents and strategies for MF (17:31) Splenic response and symptomology in patients with MF (25:36) CME information and select publications

Featuring an interview with Dr Ruben Mesa, including the following topics: Managing myelofibrosis (MF) before the availability of ruxolitinib (0:00) Pathobiology and mutational profile of MF (7:33) Matching treatments to individual patients with MF (13:25) Case: A man in his early 70s with MF and worsening anemia (17:13) Case: A man in his late 60s initially diagnosed with polycythemia vera now with MF requiring therapy (23:15) Case: A woman in her mid 60s with MF that has a suboptimal response to first-line JAK inhibitor therapy (30:25) Efficacy and safety of novel agents and strategies for MF (35:40) CME information and select publications

Featuring perspectives from Drs Ursula Matulonis and Debra Richardson, including the following topics: PROLOGUE: Antibody-Drug Conjugates Across Oncology (0:00) Antibody-Drug Conjugates in Ovarian Cancer: Mirvetuximab Soravtansine (10:03) Antibody-Drug Conjugates in Ovarian Cancer: Upifitamab Rilsodotin (29:09) Tumor Treating Fields (41:35) PARP Inhibitor Update (47:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr Toni Choueiri, including the following topics: Evolution in the management of renal cell carcinoma (RCC) (0:00) Adjuvant therapy for intermediate- or high-risk RCC (1:52) Front-line therapy for patients with metastatic RCC (8:39) New agents for the treatment of relapsed or refractory RCC (16:24) Mechanism of action and efficacy of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (19:56) CME information and select publications

Featuring an interview with Dr Toni Choueiri, including the following topics: Case: A woman in her early 70s with a large kidney tumor and multiple pulmonary nodules (0:00) Case: A woman in her early 60s diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12:52) Approach to adjuvant treatment for RCC (16:14) Examining differences between PD-1 and PD-L1 inhibitors (20:09) Management of non-clear cell RCC (24:10) Challenges in identifying patients with RCC who are more likely to benefit from immune checkpoint inhibitors (28:22) Mechanisms of action of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (30:31) Future directions in the care of patients with RCC (36:24) CME information and select publications

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: Anti-PD-1 and PD-L1 Monotherapy for NSCLC — Dr Stephen Liu CME information and select publications

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Current Treatment Landscape for Non-Small Cell Lung Cancer (NSCLC) — Dr John Heymach CME information and select publications

Featuring perspectives from Drs John Heymach and Stephen Liu, including the following topics: Introduction (0:00) Current Immunotherapy-Based Strategies for Non-Small Cell Lung Cancer (NSCLC) (9:29) Future Directions in the Management of NSCLC (37:09) CME information and select publications

Featuring perspectives from Dr Lisa Carey, including the following topics: Introduction: Journal Club with Lisa A Carey, MD, ScM (0:00) Case: A woman in her late 70s presents with triple-positive breast cancer and a suspicious mass in the liver — Zanetta S Lamar, MD (8:51) Case: A woman in her mid 40s with ER/PR-negative, HER2-positive metastatic breast cancer with a complete response to paclitaxel/trastuzumab/pertuzumab develops multiple brain metastases 3 months later — Niyati A Nathwani, MD (19:01) Case: A woman in her mid 30s with triple-positive breast cancer develops brain metastases 5 years after primary neoadjuvant treatment — Rahul Gosain, MD (22:23) Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer experiences progressive disease after abemaciclib/ovarian function suppression and an aromatase inhibitor — Laila Agrawal, MD (28:22) Case: A woman in her early 60s with ER/PR-positive, HER2-negative localized breast cancer develops triple-positive metastatic breast cancer — Mamta Choksi, MD (41:16) Case: A woman in her early 50s with 1.2-cm triple-positive breast cancer who underwent mastectomy (surgical specimen HER2-negative) and adjuvant paclitaxel/trastuzumab now presents with HER2-negative localized recurrence — Namrata I Peswani, MD (43:37) Faculty Survey (47:53) Ongoing Trials; Reported Data; Review Articles (55:01) CME information and select publications

Featuring a slide presentation and related discussion from Professor Arndt Vogel, including the following topics: Advances in first-line treatment for patients with advanced hepatocellular carcinoma (HCC) (0:00) Outcomes of Phase III clinical trials evaluating single-agent immunotherapy as initial treatment for advanced HCC (4:19) Immune checkpoint inhibitors as second-line treatment for recurrent HCC (6:03) Combination therapy as initial treatment for advanced HCC (8:05) Sequencing therapies for advanced HCC (13:20) Future directions in caring for patients with advanced HCC (22:43) CME information and select publications

Featuring an interview with Professor Arndt Vogel, including the following topics: Case: A man in his early 40s with hepatitis B virus infection and hepatocellular carcinoma (HCC) with Child-Pugh C, ALBI 3 cirrhosis (0:00) Case: A man in his late 60s with metastatic HCC with Child-Pugh A, ALBI 2 cirrhosis (7:54) Case: A man in his early 70s with rheumatoid arthritis diagnosed with Barcelona Clinic Liver Cancer Stage 2 HCC (10:54) The etiology of HCC and response to immunotherapy (13:20) Evaluating recent first-line Phase III combination trials for unresectable HCC (19:57) Managing treatment-emergent adverse events with combination therapies for advanced HCC (25:47) Potential long-term benefits of immunotherapy-based treatments (29:33) Impact of recent changes in HCC treatment algorithms on the use of local therapy (31:46) Use of neoadjuvant therapy to convert unresectable HCC to resectable disease (37:00) Using tyrosine kinase inhibitors for patients with HCC and comorbidities (44:22) CME information and select publications

Featuring an interview with Dr Eytan Stein, including the following topics: Practical considerations for using venetoclax/HMA (hypomethylating agent) combinations in the management of acute myeloid leukemia (AML) (0:00) Approach to transplant for older patients with AML (10:33) Potential availability of magrolimab and sabatolimab in clinical practice (13:04) ASH 2022 preview: Investigational therapies excluding transplantation and cellular immunotherapies (17:33) Activity, tolerability and future directions with FLT3 and IDH inhibitors in AML (22:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics: Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00) Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19) Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27) Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34) Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01) Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in melanoma. Featuring perspectives from Prof Georgina Long, including the following topics: Neoadjuvant and Adjuvant Therapy for Melanoma (0:00) Update on the Management of Metastatic Melanoma (19:23) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells Messersmith and John Strickler, including the following topics: Immunotherapy for Gastroesophageal Cancers; PARP Inhibitors in Pancreatic Cancer (0:00) HER2-Positive Gastroesophageal and Colorectal Cancer; Role of Circulating Tumor DNA/Minimal Residual Disease in Colorectal Cancer (20:21) Colorectal Cancer in Younger Patients; Tumor Microbiome (45:51) Neoadjuvant Therapy for Microsatellite Instability-High Gastroesophageal and Colorectal Cancer (47:53) Novel Agents in Pancreatic Cancer (53:14) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in ovarian cancer. Featuring perspectives from Dr David O'Malley, including the following topics: Primary Maintenance Therapy for OC (0:00) Current Management of Relapsed Disease (20:43) CME information and select publications